Dyadic International (NASDAQ:DYAI) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Dyadic International (NASDAQ:DYAI) announced its earnings results on Wednesday. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02), FiscalAI reports. The company had revenue of $0.96 million during the quarter, compared to analyst estimates of $1.02 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.

Dyadic International Stock Down 15.3%

Shares of NASDAQ DYAI traded down $0.16 during midday trading on Wednesday, reaching $0.89. The company’s stock had a trading volume of 316,690 shares, compared to its average volume of 180,259. The stock has a 50 day simple moving average of $0.96 and a 200-day simple moving average of $0.86. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. The stock has a market capitalization of $32.42 million, a price-to-earnings ratio of -3.87 and a beta of 1.12. Dyadic International has a fifty-two week low of $0.65 and a fifty-two week high of $1.60.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $3.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in DYAI. Bank of America Corp DE lifted its position in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. bought a new position in shares of Dyadic International in the 3rd quarter valued at about $190,000. Finally, Geode Capital Management LLC grew its holdings in shares of Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 36,266 shares in the last quarter. Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.